Fundraising FoxBridge Therapeutics
Birmingham, US · Founded 2016 · Delaware corporation
Find your way into Bridge Therapeutics
Sign up to see every warm intro you have to Bridge Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Bridge Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Bridge Therapeutics is a development-stage pharmaceutical company developing BT-219 (Bunalz), a buprenorphine/naloxone orally disintegrating tablet for Opioid Use Disorder, and BT-205, a buprenorphine/meloxicam sublingual combination for chronic pain in opioid-experienced patients. Both drug candidates are being pursued through the FDA 505(B)(2) approval pathway.
Founders & leadership
Reported raises · per SEC filings
Form D private placements$2.3M disclosed across 2 rounds · 2019–2023
▶$321KraisedDec 2023 · 22 investors · PharmaceuticalsRule 506(c)
- Christopher PalutisDirector
- Joseph Patrick MullinDirector
- Elizabeth KelleyDirector
- Jason BaileyDirector
- Timothy Grant PearaExecutive Officer
- James Gregory SullivanExecutive Officer, Director
- Offering amount
- $1.5M
- Amount sold
- $321K
- Minimum investment
- $2K
- First sale
- Oct 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06c
▶$2MraisedApr 2019 · 11 investors · PharmaceuticalsRule 506(c)
- Joseph MullinDirector
- David H BergstromDirector
- Elizabeth KelleyDirector
- Tim PearaExecutive Officer
- James G SullivanExecutive Officer, Director
- Russell KelleyPromoter
- Diana HarshbargerDirector
- Kelley S AltonExecutive Officer, Director
- Amount sold
- $2M
- Minimum investment
- $25K
- Sales commissions
- $20K
- Placement agents
- Emerson Equity LLC
- First sale
- Apr 2019
- Incorporated
- Corporation, Delaware, 2016
- Federal exemptions
- 06c
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 1
Companies working in the same space as Bridge Therapeutics.
Frequently asked questions
- What does Bridge Therapeutics do?
- Bridge Therapeutics is a development-stage pharmaceutical company developing BT-219 (Bunalz), a buprenorphine/naloxone orally disintegrating tablet for Opioid Use Disorder, and BT-205, a buprenorphine/meloxicam sublingual combination for chronic pain in opioid-experienced patients. Both drug candidates are being pursued through the FDA 505(B)(2) approval pathway.
- How much funding has Bridge Therapeutics raised?
- Bridge Therapeutics has disclosed $2.3M raised across 2 rounds.
- Where is Bridge Therapeutics headquartered?
- Bridge Therapeutics is headquartered in Birmingham, US.